Domestic pharmaceutical companies win Trajenta’s crystalline patent nullification trial

Domestic pharmaceutical companies have won the crystalline patent nullification trial of ‘Trajenta,’ a new DPP-4 type antidiabetic.

Including Trajenta Duo, Trajenta imported by Boehringer and sold by Yuhan Corporation is a large drug recording annually KRW 97.2 billion last year.

Domestic companies have a strategy block the early entry of generic drugs by nullifying the patent.

According to ...